CD82 / KAI-1 Protein & Antibody

Cluster of Differentiation 82 / Kangai 1

CD82 / KAI-1 Products

CD82 / KAI-1 Protein, Recombinant

Molecule	Species	Description //For Detailed Info. and Price------CLICK!	Cat. No
CD82/KAI-1	Human	CD82/KAI-1 Protein, Recombinant	12275-H08H

CD82 / KAI-1 Antibody

Molecule	Application	Description //For Detailed Info. and Price------CLICK!	Cat. No
Human CD82/KAI-1	WB, ELISA, IHC-P	CD82 / KAI-1 Antibody (Antigen Affinity Purified)	12275-RP02
Human CD82/KAI-1	ELISA	CD82 / KAI-1 Antibody	12275-R071

CD82 / KAI-1 cDNA Clone

Molecule	Species	Description //For Detailed Info. and Price------CLICK!	Cat. No
CD82/KAI-1	Human	CD82 cDNA Clone / ORF Clone	HG12275-G
CD82/KAI-1	Mouse	Mouse CD82/KAI-1 cDNA Clone / ORF Clone	MG50744-G
CD82/KAI-1	Rat	Rat CD82 cDNA Clone / ORF Clone	RG80332-G
CD82/KAI-1	Cynomolgus	Cynomolgus monkey CD82 Gene cDNA Clone / ORF Clone	CG90202-G

CD82 / KAI-1 Related Areas

Immunology>>Cluster of Differentiation>>CD82/KAI-1

CD82 / KAI-1 Alternative Names

CD82, KAI-1, 4F9, C33, GR15, IA4, KAI1, R2, SAR2, ST6, TSPAN27 [Homo sapiens]

Cd82, KAI-1, RP23-70K10.2, AA682076, AL023070, C33, Kai1, Tspan27 [Mus musculus]

CD82 / KAI-1 Background

CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor.

CD82 / KAI-1 Related Studies

1. Malik FA, et al. (2009) KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol. 24(4): 519-30.
2. Liu WM, et al. (2006) KAI1/CD82, a tumor metastasis suppressor. Cancer Lett. 240(2): 183-94.
3. Tonoli H, et al. (2006) CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med. 11(12): 563-70.
4. Jackson P, et al. (2005) KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol. 37(3): 530-4.